How Price Transparency Caused Patients to Gripe Loudly about the Skyrocketing Cost of Mylan’s EpiPen and Why Clinical Laboratories Should Watch Next Developments

Medical laboratory managers are getting an important lesson in the power of price transparency to motivate patients to complain about arbitrarily high prices for healthcare services and products By now, most clinical laboratory managers and pathologists know about the EpiPen pricing scandal. Simply said, it illustrates all the flaws and problems in the US healthcare system that make it possible for vendors and providers to raise prices arbitrarily and stick the bill on health insurers,...

Rapid Progress in Systems Biology Predicted to Increase Multiplex Testing by Clinical Pathology Laboratories

Trend from reductionism to holistic biomedicine means clinical laboratories and pathologists should expect increased multiplex testing Systems biology (SB) is a rapidly-evolving area of research that, by itself, could greatly expand the need for multiplex testing performed by clinical laboratories. But systems biology has yet to catch the full attention of either the media or Wall Street. That may soon change. Despite the complexity of human metabolic systems, experts in systems biology are...

Thermo Fisher Trumped by Merck KGaA’s $7.2 Billion Bid to Acquire Millipore

Clinical Pathology Laboratory Customers of Millipore Not Likely to See Many Changes It only took a few days for Millipore Corporation (NYSE: MIL) to find a buyer willing to outbid Thermo Fisher Scientific Inc. (NYSE: TMO). Millipore agreed to be acquired by Merck KGaA (FWB: MRK) of Darmstadt, Germany. Merck will pay about $7.2 billion for Millipore, which tops a reported bid of $6 billion made by Thermo Fisher last week. Because many clinical pathology laboratories use Millipore’s water...
;